Showing results (341-350 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|June 23, 2011
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinomaSu Jin Lee, Jeeyun Lee, Se Hoon Park, et al.
Investigational New Drugs|December 15, 2010
Further developments for improving response and tolerance to irradiation for advanced renal cancer: concurrent (mTOR) inhibitor RAD001 and helical tomotherapyYoulia M Kirova, Vincent Servois, Cyrus Chargari, et al.
Investigational New Drugs|December 4, 2010
Deactylase inhibition in myeloproliferative neoplasmsSridurga Mithraprabhu, George Grigoriadis, Tiffany Khong, et al.
Investigational New Drugs|December 22, 2010
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malateJustine Yang Bruce, Jens Eickhoff, Roberto Pili, et al.
Investigational New Drugs|December 17, 2010
Evolution of the predictive markers amphiregulin and epiregulin mRNAs during long-term cetuximab treatment of KRAS wild-type tumor cellsCristina Oliveras-Ferraros, Anna Massaguer Vall-Llovera, Dolors Carrion Salip, et al.
Investigational New Drugs|February 23, 2011
Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in miceGrace-Ifeyinwa Onimoe, Aiguo Liu, Li Lin, et al.
Investigational New Drugs|February 26, 2011
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trialsKohei Shitara, Junko Ikeda, Tomoya Yokota, et al.
Investigational New Drugs|December 29, 2010
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapySang Joon Shin, Joong Bae Ahn, Kyung Soo Park, et al.
Investigational New Drugs|December 29, 2010
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonistJohn W Bauman, Joyce M Antal, Laurel M Adams, et al.
Investigational New Drugs|February 3, 2011
A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell linesJessica Castro, Marc Ribó, Teresa Puig, et al.
Pageof 372